Topical Delivery of microRNA-125b by Framework Nucleic Acids for Psoriasis Treatment
Yunfeng Han,Long Xi,Fang Leng,Chenjie Xu,Ying Zheng
DOI: https://doi.org/10.2147/ijn.s441353
IF: 7.033
2024-03-15
International Journal of Nanomedicine
Abstract:Yunfeng Han, 1 Long Xi, 1, 2 Fang Leng, 3 Chenjie Xu, 3 Ying Zheng 1 1 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, People's Republic of China; 2 School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, People's Republic of China; 3 Department of Biomedical Engineering, City University of Hong Kong, Hong Kong SAR, People's Republic of China Correspondence: Ying Zheng; Chenjie Xu, Tel +853 88224687 ; +852 34424169, Fax +853 28841358, Email ; Purpose: Psoriasis is a chronic and recurrent inflammatory dermatitis characterized by T cell imbalance and abnormal keratinocyte proliferation. MicroRNAs (miRNAs) hold promise as therapeutic agents for this disease; however, their clinical application is hindered by poor stability and limited skin penetration. This study demonstrates the utilization of Framework Nucleic Acid (FNA) for the topical delivery of miRNAs in psoriasis treatment. Methods: By utilizing miRNA-125b as the model drug, FNA-miR-125b was synthesized via self-assembly. The successful synthesis and stability of FNA-miR-125b in bovine fetal serum (FBS) were verified through gel electrophoresis. Subsequently, flow cytometry was employed to investigate the cell internalization on HaCaT cells, while qPCR determined the effects of FNA-miR-125b on cellular functions. Additionally, the skin penetration ability of FNA-miR-125b was assessed. Finally, a topical administration study involving FNA-miR-125b cream on imiquimod (IMQ)-induced psoriasis mice was conducted to evaluate its therapeutic efficacy. Results: The FNA-miR-125b exhibited excellent stability, efficient cellular internalization, and potent inhibition of keratinocyte proliferation. In the psoriasis mouse model, FNA-miR-125b effectively penetrated the skin tissue, resulting in reduced epidermal thickness and PASI score, as well as decreased levels of inflammatory cytokines. Keywords: psoriasis, topical delivery, miRNA-125b, framework nucleic acid, FNA Graphical Psoriasis is a chronic and recurrent inflammatory dermatitis that manifests with both physical and physiological symptoms. 1 It primarily arises from an imbalance in T cell populations, as well as the abnormal proliferation and aberrant differentiation of keratinocytes. 1,2 Therefore, the treatment strategies of psoriasis focus on inhibit the T helper cell function or hyperplasia of keratinocyte. Existing therapies focus on temporarily relieving the symptoms using immunosuppressive drugs such as cyclosporine and methotrexate and monoclonal antibodies like TNF-α and IL-17 antibodies. 3 However, there is still no cure for psoriasis. There is a great need to develop drugs that can cure or have long-term effect in relieving the symptoms. 4 microRNAs (miRNAs), which are small non-coding RNAs, play significant roles in RNA-silencing and post-transcriptional gene expression regulation. Thus, up-regulation or reduction of a specific miRNA may directly or indirectly regulate T cell imbalance and excessive proliferation of keratinocytes. 2 Studies have identified over 250 miRNAs that exhibit abnormal expression patterns in psoriasis patients, some of which regulate crucial cellular processes such as proliferation, 5,6 differentiation, 7,8 apoptosis, 9 cytokine production 10 and distort T cell subset balance. 2,11,12 Consequently, targeting miRNA has emerged as a promising therapeutic approach for managing psoriasis. 13 There are two approaches in miRNA-based therapy: miRNA inhibition and miRNA replacement. In the former approach, synthetic single-stranded RNAs act as miRNA antagonists (antagomirs) to inhibit the action of endogenous miRNAs. For the replacement approach, miRNA mimics are utilized to mimic the function of endogenous miRNAs, resulting in mRNA degradation/inhibition and inducing a gene silencing effect. For instance, inhibition of miR-210 expression using antagomir-210 reduced Th1 and Th17 differentiation, thereby alleviating symptoms in a mouse model of psoriasis. 14 In another approach, transfection of microRNA-125b (miR-125b) mimic would markedly reduce the HaCaT cell proliferation. 8,15–17 miR-125b has been shown to have multiple targets in the proliferation of keratinocyte, such as fibroblast growth factor receptor 2 (FGFR2), 6 ubiquitin specific peptidase 2 (USP2), 8 AKT serine/threonine kinase 3 (AKT3) 16 and Bromodomain-containing protein 4 (BRD4). 17 More importantly, Signal Transducer and Activator of Transcripti -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology